SUBSCRIBE
SUBSCRIBE

Neuro3d’s Third Round: EUR31.5M For Development Of Lead Drugs

October 19, 2005 | 
1 min read

PARIS - Neuro3d closed a third round of financing in which it raised €31.5 million (US$41.6 million) from eight European venture capital funds.

Europe
MORE ON THIS TOPIC
Sanofi's Distribution Center in Quebec, Canada
Radiopharmaceuticals
Sanofi Inks $326M Radiopharma Deal With Orano
October 17, 2024
 · 
2 min read
 · 
Tristan Manalac
Leadership concept with chess figures. 3D Rendering
Obesity
Lilly’s Sprawling Obesity Clinical Program Underscores Challenges for Biotechs
October 9, 2024
 · 
3 min read
 · 
Annalee Armstrong
Pictured: Exterior view of the headquarters of the
FDA
Sanofi and Regeneron’s Dupixent Snags First Biologic Approval in COPD
September 27, 2024
 · 
2 min read
 · 
Kate Goodwin
Corporate headquarters of Novo Nordisk. A pharmaceutical company headquartered in Denmark. Copenhagen, Denmark - august 12, 2023.
Regulatory
Novo Secures EU Panel’s Backing for Cardiovascular Use of Wegovy
September 20, 2024
 · 
2 min read
 · 
Tristan Manalac